Organon India will be established in India as a wholly-owned subsidiary of Organon & Co, a global healthcare company specialising in women's healthcare. The company will concentrate its efforts on making every woman's day healthier. Organon's portfolio in India will include women's healthcare, fertility, dermatology, respiratory, and bone health products. Organon India will be operating with its in-house sales force and alliance partners across the various markets.
The company states that "At Organon, we envision a better and healthier every day for every woman. The diversity of our business provides a sustainable engine of growth so we can identify and invest in solutions for women. Our mission is to deliver impactful medicines and solutions for a healthier every day."
“As a business strategy, we will listen to women to understand their healthcare needs and find solutions which are relevant to them. We will consistently make efforts to ensure availability and access to quality healthcare products for women,” said Anjan Sen, who will lead the operations for India and countries in the South Asia region.
Today, the Organon Executive Leadership Team will ring the opening bell at the New York Stock Exchange (NYSE) to mark the start of active trading.
Recognizing the importance of listening to and acting on women's experiences in order to address the challenges in women's health, Organon gathered voices from around the world to create the 'Wall of Voices,' a multimedia installation outside the NYSE that shared powerful perspectives, voices, and images.
Merck & Co. announced in May 2020 that Organon & Co. will be the name of "the pending spin-off of its women's health, legacy products, and biosimilars businesses, which the company claims will be completed by the end of the first half of 2021."
Improving women’s health is critical for achieving a healthier world. Organon & Co is united in the drive to better support the health of women within the company and around the globe.
